Limits...
Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.

Ando T, Hosokawa A, Yoshita H, Ueda A, Kajiura S, Mihara H, Nanjo S, Fujinami H, Nishikawa J, Ogawa K, Nakajima T, Imura J, Sugiyama T - Gastroenterol Res Pract (2015)

Bottom Line: Methods.Conclusion.Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, Japan.

ABSTRACT
Objective. Patients with gastroenteropancreatic neuroendocrine carcinoma (NEC) have a poor prognosis. Platinum-based combination chemotherapy is commonly used as first-line treatment; however, the role of salvage chemotherapy remains unknown. This study aimed to analyze the efficacy and safety of amrubicin monotherapy in patients with platinum-refractory gastroenteropancreatic NEC. Methods. Among 22 patients with advanced gastroenteropancreatic NEC, 10 received amrubicin monotherapy between September 2007 and May 2014 after failure of platinum-based chemotherapy. The efficacy and toxicity of the treatment were analyzed retrospectively. Results. Eight males and two females (median age, 67 years (range, 52-78)) received platinum-based chemotherapy, including cisplatin plus irinotecan (n = 7, 70%), cisplatin plus etoposide (n = 2, 20%), and carboplatin plus etoposide (n = 1, 10%) before amrubicin therapy. Median progression-free survival and overall survival after amrubicin therapy were 2.6 and 5.0 months, respectively. Two patients had partial response (20% response rate), and their PFS were 6.2 months and 6.3 months, respectively. Furthermore, NEC with response for amrubicin had characteristics with a high Ki-67 index and receipt of prior chemotherapy with cisplatin and irinotecan. Grade 3-4 neutropenia and anemia were observed in four and five patients, respectively. Conclusion. Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC.

No MeSH data available.


Related in: MedlinePlus

The association between response to amrubicin therapy and the Ki-67 index or previous chemotherapy.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4493294&req=5

fig2: The association between response to amrubicin therapy and the Ki-67 index or previous chemotherapy.

Mentions: The overall RR was 20% (95% CI, 4.7%–44.7%), and the disease control rate was 60.0% (95% CI, 29.6%–90.3%). Two patients with pancreatic or gastric NEC had a partial response, and their PFS was 6.2 months and 6.3 months, respectively. The tumor response, Ki-67 index, and first-line chemotherapy were illustrated to analyze the characteristics of NEC in response to amrubicin (Figure 2). Two patients with partial response had characteristics of NEC with a high Ki-67 index (99% and 89%, resp.), and they had received cisplatin and irinotecan as a first-line treatment. On the other hand, all three patients receiving cisplatin and etoposide as first-line treatment, including the topoisomerase II inhibitor, had progressive disease.


Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.

Ando T, Hosokawa A, Yoshita H, Ueda A, Kajiura S, Mihara H, Nanjo S, Fujinami H, Nishikawa J, Ogawa K, Nakajima T, Imura J, Sugiyama T - Gastroenterol Res Pract (2015)

The association between response to amrubicin therapy and the Ki-67 index or previous chemotherapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4493294&req=5

fig2: The association between response to amrubicin therapy and the Ki-67 index or previous chemotherapy.
Mentions: The overall RR was 20% (95% CI, 4.7%–44.7%), and the disease control rate was 60.0% (95% CI, 29.6%–90.3%). Two patients with pancreatic or gastric NEC had a partial response, and their PFS was 6.2 months and 6.3 months, respectively. The tumor response, Ki-67 index, and first-line chemotherapy were illustrated to analyze the characteristics of NEC in response to amrubicin (Figure 2). Two patients with partial response had characteristics of NEC with a high Ki-67 index (99% and 89%, resp.), and they had received cisplatin and irinotecan as a first-line treatment. On the other hand, all three patients receiving cisplatin and etoposide as first-line treatment, including the topoisomerase II inhibitor, had progressive disease.

Bottom Line: Methods.Conclusion.Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, Japan.

ABSTRACT
Objective. Patients with gastroenteropancreatic neuroendocrine carcinoma (NEC) have a poor prognosis. Platinum-based combination chemotherapy is commonly used as first-line treatment; however, the role of salvage chemotherapy remains unknown. This study aimed to analyze the efficacy and safety of amrubicin monotherapy in patients with platinum-refractory gastroenteropancreatic NEC. Methods. Among 22 patients with advanced gastroenteropancreatic NEC, 10 received amrubicin monotherapy between September 2007 and May 2014 after failure of platinum-based chemotherapy. The efficacy and toxicity of the treatment were analyzed retrospectively. Results. Eight males and two females (median age, 67 years (range, 52-78)) received platinum-based chemotherapy, including cisplatin plus irinotecan (n = 7, 70%), cisplatin plus etoposide (n = 2, 20%), and carboplatin plus etoposide (n = 1, 10%) before amrubicin therapy. Median progression-free survival and overall survival after amrubicin therapy were 2.6 and 5.0 months, respectively. Two patients had partial response (20% response rate), and their PFS were 6.2 months and 6.3 months, respectively. Furthermore, NEC with response for amrubicin had characteristics with a high Ki-67 index and receipt of prior chemotherapy with cisplatin and irinotecan. Grade 3-4 neutropenia and anemia were observed in four and five patients, respectively. Conclusion. Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC.

No MeSH data available.


Related in: MedlinePlus